Evidence map›Paper›PMID 35358998›Full record

ArticleBlood advances2023

The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia.

Clare Sun, Yun-Ching Chen, Aina Martinez Zurita, Maria Joao Baptista, Stefania Pittaluga, Delong Liu, Daniel Rosebrock, Satyen Harish Gohil, Nakhle S Saba, Theresa Davies-Hill and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00923507 (Natural History Study of Monoclonal B Cell Lymphocytosis), which is not on this map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00923507 recruitingnot on this map

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

TypeobservationalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2008Enrolled1,000ConditionsWaldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Monoclonal B-Cell Lymphocytosis, Small Lymphocytic Lymphoma
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Clare SunHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-8498-4729
Yun-Ching ChenBioinformatics and Computational Biology Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Aina Martinez ZuritaBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.ORCID 0000-0001-9300-872X
Maria Joao BaptistaJosep Carreras Leukaemia Research Institute, IJC Can Ruti Campus, Barcelona, Spain.ORCID 0000-0003-3471-2535
Stefania PittalugaLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-7688-1439
Delong LiuBioinformatics and Computational Biology Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Daniel RosebrockBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.ORCID 0000-0002-4818-4983
Satyen Harish GohilBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
Nakhle S SabaSection of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, LA.
Theresa Davies-HillLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Sarah E M HermanHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Gad GetzBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
Mehdi PiroozniaBioinformatics and Computational Biology Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-4210-6458
Catherine J WuBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.ORCID 0000-0002-3348-5054
Adrian WiestnerHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
National Institutes of Health · USBroad Institute · USJosep Carreras Leukaemia Research Institute · ESTulane University · US

Funding

Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapyZIAHL002346 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2009 to 2025
$29.8M
ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0M
Immunotherapy of low grade lymphoid malignanciesZIAHL006070 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2010 to 2025
$15.9M
Personal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6M
NCI NIH HHS P01 CA206978NCI NIH HHS R01 CA155010
6 · The paper itself

Abstract

In chronic lymphocytic leukemia (CLL), B-cell receptor signaling, tumor-microenvironment interactions, and somatic mutations drive disease progression. To better understand the intersection between the microenvironment and molecular events in CLL pathogenesis, we integrated bulk transcriptome profiling of paired peripheral blood (PB) and lymph node (LN) samples from 34 patients. Oncogenic processes were upregulated in LN compared with PB and in immunoglobulin heavy-chain variable (IGHV) region unmutated compared with mutated cases. Single-cell RNA sequencing (scRNA-seq) distinguished 3 major cell states: quiescent, activated, and proliferating. The activated subpopulation comprised only 2.2% to 4.3% of the total tumor bulk in LN samples. RNA velocity analysis found that CLL cell fate in LN is unidirectional, starts in the proliferating state, transitions to the activated state, and ends in the quiescent state. A 10-gene signature derived from activated tumor cells was associated with inferior treatment-free survival (TFS) and positively correlated with the proportion of activated CD4+ memory T cells and M2 macrophages in LN. Whole exome sequencing (WES) of paired PB and LN samples showed subclonal expansion in LN in approximately half of the patients. Since mouse models have implicated activation-induced cytidine deaminase in mutagenesis, we compared AICDA expression between cases with and without clonal evolution but did not find a difference. In contrast, the presence of a T-cell inflamed microenvironment in LN was associated with clonal stability. In summary, a distinct minor tumor subpopulation underlies CLL pathogenesis and drives the clinical outcome. Clonal trajectories are shaped by the LN milieu, where T-cell immunity may contribute to suppressing clonal outgrowth. The clinical study is registered at clinicaltrials.gov as NCT00923507.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAnimalsDisease ProgressionGenetic HeterogeneityImmunoglobulin Variable RegionMiceSignal TransductionTumor MicroenvironmentImmunoglobulin Variable Region

Identifiers

PMID35358998
PMCPMC9811214
OpenAlexW4220770941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.